References
- Cao A, Galanello R. β-Thalassemia. Genet Med. 2010;12(2):61–76.
- Makis A, Hatzimichael E, Papassotiriou I, et al. 2017 Clinical trials update in new treatments of β-thalassemia. Am J Hematol. 2016;91(11):1135–1145.
- Origa R. β-Thalassemia. Genet Med. 2017;19(6):609–619.
- Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13(9):1096–1101.
- Hassan MA, Tolba OA. Iron chelation monotherapy in transfusion-dependent β-thalassemia major patients: a comparative study of deferasirox and deferoxamine. Electron Physician. 2016;8(5):2425–2431.
- Mokhtar GM, Gadallah M, El Sherif NH, et al. Morbidities and mortality in transfusion-dependent β-thalassemia patients (single-center experience). Pediatr Hematol Oncol. 2013;30(2):93–103.
- Maggio A, Filosa A, Vitrano A, et al. Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trials. Blood Cells Mol Dis. 2011;47(3):166–175.
- Shamsian BS, Esfahani SA, Milani H, et al. Magnetic resonance imaging in the evaluation of iron overload: a comparison of MRI, echocardiography and serum ferritin level in patients with β-thalassemia major. Clin Imaging. 2012;36(5):483–488.
- Hashemieh M, Azarkeivan A, Akhlaghpoor S, et al. T2-star (T2*) magnetic resonance imaging for assessment of kidney iron overload in thalassemic patients. Arch Iran Med. 2012;15(2):91–94.
- Kontoghiorghes GJ. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. Hemoglobin. 2006;30(2):183–200.
- Treesirichod A, Chansakulporn S, Wattanapan P. Correlation between skin color evaluation by skin color scale chart and narrowband reflectance spectrophotometer. Indian J Dermatol. 2014;59(4):339–342.
- Taylor S, Westerhof W, Im S, et al. Noninvasive techniques for the evaluation of skin color. J Am Acad Dermatol. 2006;54(5Suppl2):S282–S290.
- Russo V, Rago A, Papa AA, et al. Electrocardiographic presentation, cardiac arrhythmias, and their management in β-thalassemia major patients. Ann Noninvasive Electrocardiol. 2016;21(4):335–342.
- Cunningham MJ, Macklin EA, Neufeld EJ, et al. Thalassemia Clinical Research Network. Complications of β-thalassemia major in North America. Blood. 2004;104(1):34–39.
- Salama KM, Ibrahim OM, Kaddah AM, et al. Liver enzymes in children with β-thalassemia major: correlation with iron overload and viral hepatitis. Open Access Maced J Med Sci. 2015;3(2):287–292.
- Pantopoulos K, Porwal SK, Tartakoff A, et al. Mechanisms of mammalian iron homeostasis. Biochemistry. 2012;51(29):5705–5724.
- Gorodetsky R, Goldfarb A, Dagan I, et al. Noninvasive analysis of skin iron and zinc levels in β-thalassemia major and intermedia. J Lab Clin Med. 1985;105(1):44–51.
- Rasool M, Malik A, Jabbar U, et al. Effect of iron overload on renal functions and oxidative stress in β thalassemia patients. Saudi Med J. 2016;37(11):1239–1242.
- Ibrahim MH, Azab AA, Kamal NM, et al. Early detection of myocardial dysfunction in poorly treated pediatric thalassemia children and adolescents: two Saudi centers experience. Ann Med Surg (Lond). 2016;9:6–11.
- Altincik A, Akin M. Prevalence of endocrinopathies in Turkish children with β-thalassemia major: a single-center study. J Pediatr Hematol Oncol. 2016;38(5):389–393.
- Kitazawa M, Iwasaki K, Sakamoto K. Iron chelators may help prevent photoaging. J Cosmet Dermatol. 2006;5(3):210–217.
- Roberts WE. Skin type classification systems old and new. Dermatol Clin. 2009;27(4):529–533.
- Youssry I, Mohsen NA, Shaker OG, et al. Skin iron concentration: a simple, highly sensitive method for iron stores evaluation in thalassemia patients. Hemoglobin. 2007;31(3):357–365.
- Lerner NBC. The anemias. In: Kliegman RM, Stanton BF, St. Geme JW, et al., editors. Nelson textbook of pediatrics. Chap. 441, 19th ed. Philadelphia (PA): Elsevier/Saunders; 2011.